Braftovi (Encorafenib) for Melanoma

Overview
Braftovi is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to be used in combination with binimetinib to treat people who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation (change), as detected by an FDA-approved test. Braftovi is also known by its drug name, encorafenib. 

Braftovi is a member of a class of drugs called kinase inhibitors. Braftovi works by inhibiting the BRAF protein, which is involved in cell growth and replication, and the medication specifically targets BRAF V600E receptors. This action helps slow down or stop the progression of the cancer.

How do I take it?
Prescribing information states that Braftovi is usually taken orally (by mouth) as a tablet once daily, along with binimetinib. 

Braftovi should be taken exactly as prescribed by a doctor.

Side effects
The FDA-approved label for Braftovi lists common side effects for Braftovi plus binimetinib including fatigue, nausea, vomiting, abdominal pain, and arthralgia (joint pain).

Rare but serious side effects include new primary cancers, increased cell numbers in BRAF wild-type tumors, hemorrhage (heavy bleeding), uveitis (eye inflammation), QT prolongation (a heart rhythm condition), and fetal harm.

For more details about this treatment, visit:

Braftovi — Pfizer

Braftovi — Drugs.com

Encorafenib (Braftovi) — OncoLink